ArticleOxford medical case reports2026
Selective cTACE to a segment target hepatocellular carcinoma lesion during atezolizumab plus bevacizumab therapy achieving delayed hypovascularization and shrinkage of non-target intrahepatic lesions: a case report.
Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atezolizumab plus bevacizumab (Atez/Bev) is the standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). We report HCC with intrahepatic progression during Atez/Bev in which selective conventional transarterial chemoembolization (cTACE) to a single lesion was followed by non-target lesion shrinkage. An 82-year-old woman with metabolic dysfunction-associated steatotic liver disease was diagnosed with BCLC stage B hepatocellular carcinoma in segments 5/7. After TACE, residual viable tumor persisted in segment 5, and Atez/Bev was initiated. After 4 cycles, a new intrahepatic lesion appeared in segment 8, and after 7 cycles, lesions in segments 5/7/8 enlarged, meeting the mRECIST progressive disease criteria. Systemic therapy continued, and selective cTACE for the segment 5 lesion was added. At 3 months post-cTACE, segment 5 viability decreased, but overall mRECIST remained progressive disease. At 6 months (November 20XX + 1), arterial enhancement in segment 5 resolved and non-target segment 7/8 lesions became hypovascular and shrank, achieving partial response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.